PharmaSUG2023paper·US·Solution Development
Low Code Approach to Clinical Application Development using SAS Studio Custom Step SD-335
Official-source directory
Conference Papers
13,885
available papers
10
available conferences
Papers
Showing 4201–4220 of 13,885
PharmaSUG2023paper·US·Statistics and Analytics
A Macro to Apply Exclusion Criteria to SAS(r) PK data SA-019
PharmaSUG2023paper·US·Statistics and Analytics
Validating novel maraca plots – R and SAS love story SA-068
PharmaSUG2023paper·US·Statistics and Analytics
Picking Scabs and Digging Scarabs: Refactoring User-Defined Decision Table Interpretation Using the SAS® Hash Object To Maximize Efficiency and Minimize Metaprogramming SA-092
PharmaSUG2023paper·US·Statistics and Analytics
Deep Learning to Classify Adverse Events from Patient Narratives SA-110
PharmaSUG2023paper·US·Statistics and Analytics
Sensitivity Analysis for Missing Data Using Control-based Pattern Imputation SA-188
PharmaSUG2023paper·US·Statistics and Analytics
Shifting the drug development paradigm with Adaptive Design and master protocol SA-228
PharmaSUG2023paper·US·Statistics and Analytics
Statistical Considerations and Methods for Handling Missing Outcome Data in Clinical Trials During the Era of COVID-19 SA-269
PharmaSUG2023paper·US·Statistics and Analytics
SAS-based Method for PK Noncompartmental Analysis and Validation SA-284
PharmaSUG2023paper·US·Statistics and Analytics
Guidelines for the Statistical Analysis in German Dossier Submissions SA-285
PharmaSUG2023paper·US·Statistics and Analytics
A Pain in My ISR – A Primer on Injection Site Reactions SA-303
PharmaSUG2023paper·US·Strategic Implementation & Innovation
What’s the story in your subgroup analysis SI-005
PharmaSUG2023paper·US·Strategic Implementation & Innovation
Digital Data Flow (DDF) and Technological Solution Providers SI-006
PharmaSUG2023paper·US·Strategic Implementation & Innovation
Fitting Logitoid-Normal distributions with MLE estimate by SAS SEVERITY and FCMP procedures SI-016
PharmaSUG2023paper·US·Strategic Implementation & Innovation
We Can Work it Out: Dos and Don’ts for Small Biotech and CRO NDA/BLA submission partnership SI-055
PharmaSUG2023paper·US·Strategic Implementation & Innovation
Key Safety Assessments following Chimeric Antigen Receptor (CAR) T-cell Therapy in Early Development Oncology SI-088
PharmaSUG2023paper·US·Strategic Implementation & Innovation
Key Statistical Programming Considerations in External Collaborative Clinical Trials SI-102
PharmaSUG2023paper·US·Strategic Implementation & Innovation
Automation of Dataset Programming Based on Dataset Specification SI-106
PharmaSUG2023paper·US·Strategic Implementation & Innovation
Integrating Practices: How Statistical Programmers Differ and Align Within User Groups SI-139